Search Results 241-250 of 23176 for B cell lymphomas

  1. Hematology - Clinical trials

    Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas. Rochester, Minn. This is a Phase 1b ...

  2. Non-Hodgkin lymphoma - Doctors and departments - Mayo Clinic

    oma, Leukemia, Cutaneous t-cell lymphoma, Skin cancer, Plasma cell ... ymphoma, B-cell lymphoma, T-cell lymphoma. Show more areas of focus for Yi ...

  3. Bispecific antibody therapy - Doctors & Departments - Mayo Clinic

    ... B-cell lymphoma, Lymphoma, Follicular lymphoma ... The rules of T-cell engagement: Current state of CAR T cells and bispecific antibodies in B-cell lymphomas.

  4. CAR-T cell therapy - Care at Mayo Clinic

    B-cell lymphomas. National Comprehensive Cancer Network. https://www.nccn ... Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.

  5. Allison C. Rosenthal, D.O. - Doctors and Medical Staff - Mayo Clinic

    B-cell lymphoma · Cutaneous b-cell lymphoma · Cutaneous t-cell lymphoma · Diffuse large b-cell lymphoma · Follicular lymphoma · Hodgkin lymphoma · Lymphoma · Non- ...

  6. A Phase I/II Study Of AZD4512 Monotherapy Or In Combination With Anticancer Agents In Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma - Mayo Clinic

    ... B-cell Non-Hodgkin Lymphoma (B-NHL). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous ...

  7. Small lymphocytic lymphoma - Doctors and departments - Mayo Clinic

    Allison C. Rosenthal, D.O.. Internist; Oncologist; Hematologist. Phoenix, AZ. Areas of focus: CAR-T cell therapy, B- ...

  8. Bispecific antibody therapy - Mayo Clinic

    Epcoritamab (Epkinly) and glofitamab (Columvi) also target CD3 and CD20 to treat diffuse large B-cell lymphoma (DLBCL) and related lymphomas. Solid tumors.

  9. Cancer Treatment Clinical Trials - Mayo Clinic Research

    ... B-cell lymphomas who have failed 1-2 prior lines of therapy. The primary objectives are to determine the maximum tolerated dose (MTD) or highest protocol ...

  10. Clinical trials - Oncology (Medical)

    Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas. Rochester, Minn. This is a Phase 1b ...